In a subacute experiment 7 apparently healthy volunteers received a daily oral dose of 5 mg nebivolol for seven days, followed by a seven-day washout period with placebo. From the first day during treatment with nebivolol, peak exercise heart rate and systolic blood pressure, as measured during a standard-ized submaximal treadmill exercise, significantly decreased by 15 % and 19% respectively. A prolonged treatment for one week did not further increase the response of exercise heart rate and systolic blood pressure to nebivolol. How-ever, the ratio of preejection period (PEPc) to left ventricular ejection time (LVETc), an indirect and valuable measure of left ventricular performance, pro-gressively and significantly decreased during the sev...
The aim of this study is to evaluate the medium term treatment effects of the beta-blocker nebivolol...
Nebivolol is a third generation beta-blocker. It is highly selective for the beta 1-adrenoceptor, an...
John CockcroftWales Heart Research Institute, University Hospital Heath Park, Cardiff, UKAbstract: N...
Nebivolol (R67555), a drug with beta-1 receptor antagonizing properties, was administered once daily...
The aim of this study was to compare the effects on left ventricular function and exercise tolerance...
Objectives: To assess the effects of antihypertensive treatment on subclinical left ventricular dysf...
AIMS: We hypothesized that nebivolol, a beta-blocker with nitric oxide-releasing properties, cou...
Abstract Background: More than 50% of the patients with heart failure have normal ejection fraction...
Abstractβ-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular medication...
Objective Earlier studies have reported that a decrease in exercise capacity might indicate endothel...
Bucindolol is a new nonselective β-adrenergic blocking agent with direct vasodilator, partial agonis...
AbstractObjectives. This study examined the long-term (3-month) effects of nebivolol, a new beta-adr...
(D-L) Nebivolol is a new beta 1-selective adrenoceptor blocker which in normal individuals preserves...
Background: The dysfunction of vascular endothelium precedes the development of atherosclerosis in p...
(beta)-blockers are standard therapy in patients with cardiovascular disease, and have become a corn...
The aim of this study is to evaluate the medium term treatment effects of the beta-blocker nebivolol...
Nebivolol is a third generation beta-blocker. It is highly selective for the beta 1-adrenoceptor, an...
John CockcroftWales Heart Research Institute, University Hospital Heath Park, Cardiff, UKAbstract: N...
Nebivolol (R67555), a drug with beta-1 receptor antagonizing properties, was administered once daily...
The aim of this study was to compare the effects on left ventricular function and exercise tolerance...
Objectives: To assess the effects of antihypertensive treatment on subclinical left ventricular dysf...
AIMS: We hypothesized that nebivolol, a beta-blocker with nitric oxide-releasing properties, cou...
Abstract Background: More than 50% of the patients with heart failure have normal ejection fraction...
Abstractβ-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular medication...
Objective Earlier studies have reported that a decrease in exercise capacity might indicate endothel...
Bucindolol is a new nonselective β-adrenergic blocking agent with direct vasodilator, partial agonis...
AbstractObjectives. This study examined the long-term (3-month) effects of nebivolol, a new beta-adr...
(D-L) Nebivolol is a new beta 1-selective adrenoceptor blocker which in normal individuals preserves...
Background: The dysfunction of vascular endothelium precedes the development of atherosclerosis in p...
(beta)-blockers are standard therapy in patients with cardiovascular disease, and have become a corn...
The aim of this study is to evaluate the medium term treatment effects of the beta-blocker nebivolol...
Nebivolol is a third generation beta-blocker. It is highly selective for the beta 1-adrenoceptor, an...
John CockcroftWales Heart Research Institute, University Hospital Heath Park, Cardiff, UKAbstract: N...